贝伐单抗联合化疗对晚期非小细胞肺癌的疗效及对血管内皮细胞生长因子表达的影响  

Effect of bevacizumab combined with chemotherapy on advanced NSCLC and the expression of vascular endothelial growth factor

作　　者：罗红兰[1] 刘凯[2] LUO Hong-lan;LIU Kai(Department of Oncology,Huanggang Central Hospital,Huanggang,Hubei　438000,China)

机构地区：[1]黄冈市中心医院肿瘤科,湖北黄冈438000 [2]黄冈市中心医院影像科,湖北黄冈438000

出　　处：《临床肺科杂志》2018年第2期220-224,共5页Journal of Clinical Pulmonary Medicine

摘　　要：目的研究贝伐单抗联合化疗对晚期非小细胞肺癌(NSCLC)的疗效及对血管内皮细胞生长因子表达的影响。方法研究对象选取我院2014年8月到2016年2月间收治的晚期NSCLC患者102例,采用随机数字法将其分为对照组和观察组,每组各51例。对照组患者行顺铂联合培美曲塞化疗方案治疗,在此基础上,观察组患者静脉滴注贝伐单抗治疗。比较两组患者的近期疗效、不良发生率及血管内皮细胞生长因子mRNA表达情况,同时治疗后随访,比较两组患者的无进展生存期和MST。结果观察组患者的DCR和ORR均明显高于对照组(χ~2=4.55,17.17;P<0.05),VEGF-A、VEGF-B、VEGF-C的mRNA表达水平均明显低于对照组(P<0.01),无进展生存期和MST均明显高于对照组(P<0.01);两组患者的各不良反应发生率比较均无明显差异(P>0.05)。结论贝伐单抗联合化疗方案治疗晚期NSCLC的临床疗效显著,且药物毒副作用小,能有效抑制血管内皮细胞生长因子mRNA表达,延长患者生存期,值得在临床推广。Objective To study the effect of bevacizumab combined with chemotherapy on advanced non-small cell lung cancer(NSCLC)and its effect on the expression of VEGF.Methods 102 patients with advanced NSCLC in our hospital from August 2014 to February 2016 were randomly divided into the control group and the observation group,51 cases in each group.The control group was treated with cisplatin and pemetrexed chemotherapy,on this basis,the observation group was treated with intravenous infusion of bevacizumab.Their short term efficacy,adverse events and the expression of VEGF mRNA were compared,and their progression of free survival and overall survival were followed-up.Results The levels of DCR and ORR were significantly higher in the observation than in the control group(χ2=4.55,17.17;P<0.05),and the expression of VEGF-A,VEGF-B and VEGF-C mRNA were significantly lower in the observation group than in the control group(P<0.01).The progression of free survival and overall survival were significantly better in the observation group than in the control group(P<0.01).There was no significant difference in the adverse reaction incidence between the two groups(P>0.05).Conclusion Bevacizumab combined with chemotherapy in treatment of advanced nonsquamous NSCLC has significantly clinical efficacy and its drug side effect is light,which can effectively inhibit the expression of vascular endothelial growth factor mRNA and prolong the survival time of patients.So it is worthy of widely clinical promotion.

关 键 词：贝伐单抗 晚期NSCLC 疗效 血管内皮细胞生长因子 

分 类 号：R734.2[医药卫生—肿瘤]